Mutant-selective degradation by BRAF-targeting PROTACs

Over 300 BRAF missense mutations have been identified in patients, yet currently approved drugs target V600 mutants alone. Moreover, acquired resistance inevitably emerges, primarily due to RAF lesions that prevent inhibition of BRAF V600 with current treatments. Therefore, there is a need for new t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nat Commun
Autori principali: Alabi, Shanique, Jaime-Figueroa, Saul, Yao, Zhan, Gao, Yijun, Hines, John, Samarasinghe, Kusal T. G., Vogt, Lea, Rosen, Neal, Crews, Craig M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7876048/
https://ncbi.nlm.nih.gov/pubmed/33568647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-21159-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi